<DOC>
	<DOCNO>NCT00000897</DOCNO>
	<brief_summary>The purpose study look effect different method birth control ( oral injectable ) body absorbs , make available , remove zidovudine ( ZDV ) . This study also evaluate difference men woman body absorbs , make available , remove ZDV . Past research show effectiveness ZDV anti-HIV drug might decrease individual use certain method birth control . ZDV may also different effect men compare woman .</brief_summary>
	<brief_title>A Study Evaluate Effects Different Methods Birth Control Drug Actions Zidovudine ( Anti-HIV Drug ) HIV-Positive Women Compare Zidovudine Metabolism Men Women</brief_title>
	<detailed_description>Oral contraceptive show substantially enhance glucuronidation several compound . One study report enhanced glucuronidation oxazepam , compound conjugate via UDP-glucuronyl transferase isozyme responsible ADV glucuronidation , suggest ZDV metabolism may alter concomitant oral contraceptive use . This potential enhancement ZDV metabolism oral contraceptive expect result decrease plasma level parent compound may lead diminished clinical efficacy woman use drug . It remain unclear whether progesterone and/or estrogen component oral contraceptive result observe glucuronidation change . This open-label , pharmacokinetic trial conduct 2 step . [ AS PER AMENDMENT 6/12/01 : The Depo-Provera IM group Step 2 fill . Female patient choose participate Step 2 may enroll Ortho-Novum 1/35 PO group . ] [ AS PER AMENDMENT 11/13/00 : Female patient may choose participate Step 1 alone Steps 1 2 . ] Male patient may participate Step 1 control arm study . In Step 1 , patient stratify sex ; Step 2 , female patient stratified choice contraception ( i.e. , oral norethindrone/ethinyl estradiol [ Ortho-Novum 1/35 ] injectable medroxyprogesterone acetate [ Depo-Provera ] ) . Step 1 ( male female ) : At entry , patient randomize receive ZDV either orally orally intravenously ( IV ) Days 7 8 . Female patient begin study ( Day 0 ) day 10-18 first day last menstrual period ( LMP ) ( Cycle 1 ) . At time enrollment , female patient [ AS PER AMENDMENT 11/13/00 : plan participate Step 2 ] choose form birth control institute Step 2 : Depo-Provera Ortho-Novum 1/35 . Male patient may enter Step 1 time . Patients continue take pre-study antiretroviral drug Step 1 . [ AS PER AMENDMENT 6/3/99 : Patients take nelfinavir may participate Depo-Provera arm . ] Days 0-6 : All patient receive oral ZDV . Day 7 : Patients randomize receive : Arm 1 ( female ) : oral ZDV total 3 dos . Arm 2 ( female ) : ZDV IV , ZDV orally total 2 oral dos . Arm 3 ( male ) : control arm . Half male patient receive ZDV Arm 1 male patient receive ZDV Arm 2 . Day 8 : Patients 3 arm receive alternate form ZDV receive Day 7 . Day 9 : Female patient resume pre-study method administration ZDV . Male patient conclude participation study Day 8 . Step 2 ( female [ AS PER AMENDMENT 11/13/00 : opting participate Step 2 ] ) : At onset second menstrual period ( Cycle 2 ) since start study , female patient start choice Ortho-Novum 1/35 intramuscularly administer Depo-Provera [ AS PER AMENDMENT 6/12/01 : Enrollment Depo-Provera close ] . Contraceptive therapy continue throughout Step 2 . Step 2 Days 0-6 : Between day 7-11 [ AS PER AMENDMENT 6/3/99 : Between day 7-18 ] third menstrual cycle ( Cycle 3 ) since start study , female patient continue pre-study antiretroviral therapy ( do Step 1 ) begin another course ZDV standard therapy 3 time daily . Days 7-8 : Patients receive original method administration ZDV ( randomize study entry ) . Female patient return final safety visit within 1 week complete study Day 8 Step 2 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Inclusion Criteria Men woman may eligible study : Are HIV positive . Women may eligible study : Have regular period normal gynecological exam , ( include Pap smear mammogram ) . Enter study Days 10 18 first day last period . Are willing use either Pill DepoProvera birth control . Have negative pregnancy test within 14 day prior study . Exclusion Criteria Men woman eligible study : Can take ZDV reason . Have cancer . Are take stavudine . Women eligible study : Can take Pill DepoProvera . Are pregnant nursing . Are receive nelfinavir want enroll Step 2 . Have history chronic high blood pressure , thrombophlebitis , and/or pulmonary embolus participate Step 2 study . ( This study change woman certain criterion exclude participate Step 2 . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Drug Interactions</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Sex Factors</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Contraceptives , Oral</keyword>
	<keyword>Progestational Hormones , Synthetic</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Estrogens</keyword>
</DOC>